SG11201408028YA - METHOD FOR PURIFICATION OF RECOMBINANT FACTOR Xa DERIVATIVES - Google Patents

METHOD FOR PURIFICATION OF RECOMBINANT FACTOR Xa DERIVATIVES

Info

Publication number
SG11201408028YA
SG11201408028YA SG11201408028YA SG11201408028YA SG11201408028YA SG 11201408028Y A SG11201408028Y A SG 11201408028YA SG 11201408028Y A SG11201408028Y A SG 11201408028YA SG 11201408028Y A SG11201408028Y A SG 11201408028YA SG 11201408028Y A SG11201408028Y A SG 11201408028YA
Authority
SG
Singapore
Prior art keywords
international
serine protease
california
applicant
rule
Prior art date
Application number
SG11201408028YA
Inventor
Genmin Lu
Uma Sinha
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of SG11201408028YA publication Critical patent/SG11201408028YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/22Affinity chromatography or related techniques based upon selective absorption processes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6432Coagulation factor Xa (3.4.21.6)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 19 December 2013 (19.12.2013) WIPOIPCT (10) International Publication Number WO 2013/188587 A1 (51) International Patent Classification: C07K1/22 (2006.01) C12N 9/64 (2006.01) (21) International Application Number: PCT/US2013/045496 (22) International Filing Date: 12 June 2013 (12.06.2013) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 61/659,821 14 June 2012 (14.06.2012) US (71) Applicant: PORTOLA PHARMACEUTICALS, INC. [US/US]; 270 E. Grand Avenue, South San Francisco, California 94080 (US). (72) Inventors: LU, Genmin; 1439 El Camino Real, Apt 9, Burlingame, California 94010 (US). SINHA, Uma; 808 Junipero Serra Blvd., San Francisco, California 94127 (US). (74) Agents: TANNER, Lorna L. et al.; Foley & Lardner LLP, 3000 K Street N.W., Suite 600, Washington, DC 20007- 5109 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) (54) Title: METHOD FOR PURIFICATION OF RECOMBINANT FACTOR Xa DERIVATIVES l> 00 00 00 T-H rn T-H o CJ o - A280 ELISA CM < 0 0- O O -O- O- O O < /: \ t \ // \ -*-V / \ / \ —£ - O O—O 0 0 0 0 A 0 80000 60000 - E 40000 < to 20000 4 6 Fraction # 10 12 r-Antidote MK r-Antidote (57) Abstract: Disclosed herein are methods and kits for purifying a serine protease. The methods entail loading the serine protease to a soybean trypsin inhibitor (STI) based affinity chromatograph, and eluting the serine protease with an elution buffer comprising an agent that disrupts interaction between the STI and the serine protease
SG11201408028YA 2012-06-14 2013-06-12 METHOD FOR PURIFICATION OF RECOMBINANT FACTOR Xa DERIVATIVES SG11201408028YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261659821P 2012-06-14 2012-06-14
PCT/US2013/045496 WO2013188587A1 (en) 2012-06-14 2013-06-12 METHOD FOR PURIFICATION OF RECOMBINANT FACTOR Xa DERIVATIVES

Publications (1)

Publication Number Publication Date
SG11201408028YA true SG11201408028YA (en) 2015-01-29

Family

ID=48700721

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201408028YA SG11201408028YA (en) 2012-06-14 2013-06-12 METHOD FOR PURIFICATION OF RECOMBINANT FACTOR Xa DERIVATIVES

Country Status (14)

Country Link
US (1) US20150239929A1 (en)
EP (1) EP2861614B1 (en)
JP (1) JP6261093B2 (en)
KR (2) KR102100629B1 (en)
CN (1) CN104379594B (en)
AU (1) AU2013274288B2 (en)
CA (1) CA2876361C (en)
ES (1) ES2612458T3 (en)
HK (1) HK1209760A1 (en)
IL (1) IL235896B (en)
PT (1) PT2861614T (en)
SG (1) SG11201408028YA (en)
WO (1) WO2013188587A1 (en)
ZA (1) ZA201408921B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140346397A1 (en) 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
US9200268B2 (en) 2012-12-27 2015-12-01 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
BE1022313B1 (en) 2014-11-28 2016-03-15 Puratos N.V. ENZYM INHIBITOR COMPLEXES
DK3472314T3 (en) * 2016-06-17 2021-07-26 Alexion Pharma Inc PREPARATION OF FACTOR XA DERIVATIVES
US20180037604A1 (en) * 2016-08-04 2018-02-08 Stelis Biopharma Private Limited Process for the purification of recombinant proteins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8528321D0 (en) * 1985-11-18 1985-12-24 Ciba Geigy Ag Modified fibrinolytic agents
KR960016514B1 (en) * 1990-10-12 1996-12-14 쿨리건 인터내셔널 컴패니 Faucet-mounted microbial filter
CN1297896A (en) * 1999-11-29 2001-06-06 中国科学技术大学 Method of extracting activated prothrombin X(FXa) effectively
EP2915564B1 (en) * 2007-09-28 2020-11-04 Portola Pharmaceuticals, Inc. Antidotes for factor XA inhibitors and methods of using the same
CA2742817A1 (en) * 2008-11-20 2010-05-27 Biogen Idec Ma Inc. Arginine inactivation of viruses
EP3604510A1 (en) * 2009-03-30 2020-02-05 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
WO2010127980A1 (en) 2009-05-05 2010-11-11 F. Hoffmann-La Roche Ag Fret-based binding assay

Also Published As

Publication number Publication date
EP2861614B1 (en) 2016-11-30
AU2013274288B2 (en) 2017-08-17
CN104379594A (en) 2015-02-25
JP2015521471A (en) 2015-07-30
CN104379594B (en) 2017-06-23
WO2013188587A1 (en) 2013-12-19
CA2876361A1 (en) 2013-12-19
EP2861614A1 (en) 2015-04-22
AU2013274288A1 (en) 2015-01-15
US20150239929A1 (en) 2015-08-27
KR102210574B1 (en) 2021-02-01
ES2612458T3 (en) 2017-05-17
PT2861614T (en) 2017-01-26
ZA201408921B (en) 2020-08-26
IL235896B (en) 2019-02-28
KR102100629B1 (en) 2020-04-16
KR20150027765A (en) 2015-03-12
JP6261093B2 (en) 2018-01-17
CA2876361C (en) 2020-06-30
HK1209760A1 (en) 2016-04-08
IL235896A0 (en) 2015-01-29
KR20200039828A (en) 2020-04-16

Similar Documents

Publication Publication Date Title
SG11201805645QA (en) Lsd1 inhibitors
SG11201908391XA (en) Methods for modulating an immune response
SG11201407900WA (en) Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof
SG11201408261UA (en) Syringe
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201804309PA (en) Antibody molecules to april and uses thereof
SG11201906885TA (en) Methods for the administration of certain vmat2 inhibitors
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201804161VA (en) Compositions comprising bacterial strains
SG11201407851RA (en) Synthesis of pyrrolo [2, 3 - b] pyridines
SG11201907840RA (en) Fused imidazo-piperidine jak inhibitors
SG11201408028YA (en) METHOD FOR PURIFICATION OF RECOMBINANT FACTOR Xa DERIVATIVES
SG11201408780XA (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
SG11201408769QA (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer
SG11201403106SA (en) Anti-phf-tau antibodies and their uses
SG11201407674TA (en) D-amino acid compounds for liver disease
SG11201807421TA (en) The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201406625XA (en) Anti-fcrn antibodies
SG11201407372UA (en) Nampt inhibitors
SG11201408174UA (en) Antibody formulation
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers